Research programme: oral factor Xa inhibitors - Roche/TeaRx

Drug Profile

Research programme: oral factor Xa inhibitors - Roche/TeaRx

Latest Information Update: 08 Jan 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Roche; TeaRx
  • Class
  • Mechanism of Action Factor Xa inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Deep vein thrombosis; Pulmonary embolism; Stroke

Most Recent Events

  • 07 Jan 2014 This programme is still in active development
  • 26 May 2011 Oral factor Xa candidates licensed to TeaRx in Russia and 12 other undisclosed countries
  • 26 May 2011 Preclinical trials in Deep vein thrombosis in Russia (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top